© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
.png?w=350&fit=crop&auto=format)
Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed Explains
Skylar Jeremias,Ashley Gallagher
July 30 2023
Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.
Julie Reed: When the US Could See Meaningful Savings From Adalimumab, Ranibizumab Biosimilar Competition
Skylar Jeremias,Ashley Gallagher
June 25 2023
Juliana (Julie) Reed, executive director of the Biosimilars Forum, predicts how long it will take for savings from adalimumab and ranibizumab biosimilar competition to fully manifest and how stakeholders can champion for better market competition for biosimilars.
Dose Rounding Can Reduce Drug Waste Costs Associated With Reference, Biosimilar Bevacizumab
Skylar Jeremias
June 19 2023
Implementing strategies, such as dose rounding, can offset the impact of drug waste and reduce the total cost of care for value-based programs, according to a recent study of practices participating in the Oncology Care Model.
Dr Fran Gregory Discusses the Future Landscape of the Biosimilars Marketplace
Pearl Steinzor
June 7 2023
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what the future biosimilars marketplace may look like compared with generics and reference products at Asembia 2023.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
Skylar Jeremias
May 28 2023
On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Biosimilar Acceptance Takes Time but Policy Intervention Is Needed, Panelists Say
Skylar Jeremias
May 25 2023
A group of panelists at Asembia 2023 shared the bigger role that pharmacists, payers, and providers can play in growing biosimilar acceptance and championing policy changes that boost biosimilar utilization.
Dr Fran Gregory: What Can We Learn From Biosimilar Use in Other Countries?
Pearl Steinzor
May 21 2023
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how the use of biosimilars in other countries strengthens the acceptance and approval of these products in the United States.
Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry
Skylar Jeremias
May 11 2023
The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.
Asembia: Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product
Skylar Jeremias
May 4 2023
In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.